Monopar Therapeutics — Director's Dealing 2019

Nov 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (NONE)
CIK: 0001645469
Period of Report: 2019-11-26

Reporting Person: RIOUX PATRICE (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-26	Common Stock	M	18333	$6	Acquired	18333	Direct
2019-11-26	Common Stock	M	100	$0.001	Acquired	18433	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-11-26	Stock options	$6	M	18333	Disposed	2027-12-31	Common Stock (18333)	Direct
2019-11-26	Stock options	$0.001	M	100	Disposed	2026-12-14	Common Stock (100)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock options	$6	2028-12-30	Common Stock (20000)	20000	Direct

Footnotes

F1: Original stock options to purchase up to 32,004 shares of common stock vested 12,000 shares upon grant date of January 1, 2018 and 1,667 shares on the first of each month thereafter.

F2: Original stock options to purchase up to 7,000 shares of common stock vested: 1,190 shares on January 15, 2017; 1,120 shares on February 15, 2017; 1,190 shares on March 15, 2017; 1,120 shares on April 15, 2017; 1,190 shares on May 15, 2017; and 1,190 shares on June 15, 2017.

F3: Stock options to purchase up to 20,000 shares of common stock vests 1,667 on January 31, 2019 and the last day of each subsequent month thereafter.